 Metabolomics studies human plasma demonstrate correlation lower plasma lysophosphatidylcholines (LPC) concentrations insulin resistance, obesity, inflammation. relationship unraveled molecular level. investigated effects abundant LPC(16:0) LPC(18:1) human skeletal muscle cells differentiated myotubes. Transcriptome analysis human myotubes treated 10muM LPC 24h revealed enrichment up-regulated peroxisome proliferator-activated receptor (PPAR) target transcripts, including ANGPTL4, PDK4, PLIN2, CPT1A. increase PDK4 ANGPTL4 RNA expression abolished presence either PPARdelta antagonist GSK0660 GSK3787. induction PDK4 LPCs blocked siRNA PPARD. activation PPARdelta transcriptional activity LPC shown PPARdelta-dependent luciferase reporter gene expression enhanced DNA binding PPARdelta/RXR dimer. functional level, results show LPC-mediated activation PPARdelta reduce fatty acid-induced inflammation ER stress human skeletal muscle cells. protective effect LPC prevented presence PPARdelta antagonist GSK0660. Taking together, LPCs activate PPARdelta, consistent association high plasma LPC levels PPARdelta-dependent anti-diabetic anti-inflammatory effects.